Filtered By:
Cancer: HER2

This page shows you your search results in order of relevance. This is page number 15.

Order by Relevance | Date

Total 260 results found since Jan 2013.

MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab.
Authors: Cataldo A, Piovan C, Plantamura I, D'Ippolito E, Camelliti S, Casalini P, Giussani M, Déas O, Cairo S, Judde JG, Tagliabue E, Iorio MV Abstract Trastuzumab is the standard treatment for HER2+ breast cancer (BC) patients, and even though it significantly improved their clinical outcome, 50% of them do not benefit from this drug and disease recurs, underlining the need of reliable predictive biomarkers and new therapeutic strategies. Strikingly, despite all the molecular analyses performed to identify the escape mechanisms behind this resistance, it still represents a question point. MiRNAs have been correl...
Source: Oncotarget - July 4, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

ASAP Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.8b00388
Source: Molecular Pharmaceutics - October 1, 2018 Category: Drugs & Pharmacology Authors: Lu Xue, Nita J. Maihle, Xiaolin Yu, Shou-Ching Tang, Hong Yan Liu Source Type: research

HER2 decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property in a NF κB-dependent way.
In this study, we explored the effect of HER2 on cancer stem cells induction and drug sensitivity of ovarian cancer cell lines. Firstly, we found that HER2 overexpression (HER2 OE) induced, while HER2 knockdown (HER2 KD) decreased CD44+/CD24- population. Consistently, HER2 expression was closely correlated with the sphere formation efficiency (SFE) of ovarian cancer cells. Secondly, we found that NFκB inhibition by specific inhibitor JSH23 or siRNA targeting subunit p65 dramatically impaired the induction of ovarian cancer stem cells by HER2, indicating that NFκB mediated HER2-induced ovarian cancer stem cells. Thirdly, ...
Source: Bioscience Reports - October 12, 2018 Category: Biomedical Science Authors: Wang W, Gao Y, Hai J, Yang J, Duan S Tags: Biosci Rep Source Type: research

Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer.
CONCLUSIONS: ERBB2 mutations hyperactivate the HER3/PI3K/AKT/mTOR axis, leading to antiestrogen resistance in ER+ breast cancer. Dual blockade of the HER2 and ER pathways is required for the treatment of ER+/HER2 mutant breast cancers. PMID: 30314968 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 12, 2018 Category: Cancer & Oncology Authors: Croessmann S, Formisano L, Kinch L, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, Mathew A, Bernicker EH, Cristofanilli M, He J, Cutler RE, Lalani AS, Miller VA, Lanman RB, Grishin N, Arteaga CL Tags: Clin Cancer Res Source Type: research

Downregulation of miRNA ‐141 in breast cancer cells is associated with cell migration and invasion: involvement of ANP32E targeting
miR ‐141 is downregulated in breast cancer (BC) tissue. Overexpression of miR‐141 inhibits BC cell migration and invasion. miR‐141 inhibits BC cell migration and invasion by directly targeting ANP32E. AbstractMicroRNAs (miRNAs) regulate many cellular activities, including cancer development, progression, and metastasis. Some miRNAs are involved in breast cancer (BC) migration and invasion, thus affect patients ’ prognosis. Microarray analysis was performed to compare miRNA expression in BC tissues, and results confirmed by qPCR. BC cell migration and invasion were studied in vitro with MDA‐MB‐231 cells using mi...
Source: Cancer Medicine - March 10, 2017 Category: Cancer & Oncology Authors: Ping Li, Tao Xu, Xin Zhou, Liangying Liao, Guolian Pang, Wan Luo, Lu Han, Jiankun Zhang, Xianyong Luo, Xiaobing Xie, Kuichun Zhu Tags: Original Research Source Type: research

Up-regulation of AREG, EGFR and HER2 contributes to increased VEGF expression in granulosa cells of patients with OHSS †.
This study demonstrated that granulosa cell-secreted AREG plays an important role in the development of OHSS, suggesting that the EGFR/HER2-mediated signaling could be a novel drug target for the prevention and treatment of OHSS. PMID: 31167229 [PubMed - as supplied by publisher]
Source: Reproductive Biology - June 4, 2019 Category: Reproduction Medicine Authors: Fang L, Yu Y, Li Y, Wang S, He J, Zhang R, Sun YP Tags: Biol Reprod Source Type: research

The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype
ConclusionWe confirm previous studies showing that the PTPN2 protein is lost in half of the breast cancer cases and gene deletion occurs in 15 –18% of the cases. Furthermore, the results suggest that the role of PTPN2 is subtype-related and should be further investigated to assess how this could affect breast cancer prognosis and treatment response.
Source: Journal of Cancer Research and Clinical Oncology - June 15, 2019 Category: Cancer & Oncology Source Type: research

The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype.
CONCLUSION: We confirm previous studies showing that the PTPN2 protein is lost in half of the breast cancer cases and gene deletion occurs in 15-18% of the cases. Furthermore, the results suggest that the role of PTPN2 is subtype-related and should be further investigated to assess how this could affect breast cancer prognosis and treatment response. PMID: 31025094 [PubMed - indexed for MEDLINE]
Source: Clinical Breast Cancer - June 30, 2019 Category: Cancer & Oncology Authors: Veenstra C, Karlsson E, Mirwani SM, Nordenskjöld B, Fornander T, Pérez-Tenorio G, Stål O Tags: J Cancer Res Clin Oncol Source Type: research

319PThe role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: A translational approach
ConclusionsOur results suggest: 1) RCL were more proliferative, more mesenchymal-like and stem cell-like properties; 2) AXL was a potential mechanism of secondary resistance to T; 3) Combination therapy with AXL inhibitor plus T restored sensitivity in in vitro model with AXL overexpression; 4) AXL expression was associated with relapse in HER2+ BC patients. These results showed AXL as a prognostic factor and a potential therapeutic target in HER2+ patients with resistance to T.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureA. Lluch: Advisory / Consultancy: Novartis; Advisor...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research

Heterogeneity and Plasticity of Human Breast Cancer Cells in Response to Molecularly-Targeted Drugs
Non-responsive subpopulation of tumor cells, and acquired resistance in initially responsive cells are major challenges for cancer therapy with molecularly-targeted drugs. While point mutations are considered the major contributing factor to acquired resistance, in this study we explored the role of heterogeneity and plasticity of selected human breast cancer cell lines (MDA-MB-231, MDA-MB-468, and AU565) in their initial and adjusted response, respectively, to ruxolitinib, everolimus, and erlotinib. After determination of lethal concentration for 50% cell death (LC50), cells were exposed to selected drugs using three diff...
Source: Frontiers in Oncology - October 14, 2019 Category: Cancer & Oncology Source Type: research

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
ConclusionsmTOR signaling is highly activated in TNBC tumors. As single rapalog treatment is insufficient to block mTOR signaling in rapalog-resistant TNBC cells, our results thus provide a potential multi-kinase inhibitor combinatorial strategy to overcome mTOR-targeted therapy resistance in TNBC cells.
Source: Breast Cancer Research and Treatment - October 17, 2019 Category: Cancer & Oncology Source Type: research

Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism
Publication date: Available online 17 December 2019Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchAuthor(s): Lingaku Lee, Irene Ramos-Alvarez, Terry W. Moody, Samuel A. Mantey, Robert T. JensenAbstractDespite recent advances in treatment of non-small cell lung cancer (NSCLC), prognosis still remains poor and new therapeutic approaches are needed. Studies demonstrate the importance of the EGFR/HER-receptor family in NSCLC growth, as well as that of other tumors. Recently, HER3 is receiving increased attention because of its role in drug resistance and aggressive growth. Activation of overexpressed G-pr...
Source: Biochimica et Biophysica Acta (BBA) Molecular Cell Research - December 18, 2019 Category: Molecular Biology Source Type: research

Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers.
Authors: Okita K, Okazaki S, Uejima S, Yamada E, Kaminaka H, Kondo M, Ueda S, Tokiwa R, Iwata N, Yamasaki A, Hayashi N, Ogura D, Hirotani K, Yoshioka T, Inoue M, Masuko K, Masuko T Abstract Resistance of progressive cancers against chemotherapy is a serious clinical problem. In this context, human epidermal growth factor receptor 3 (HER3) can play important roles in drug resistance to HER1- and HER2- targeted therapies. Since clinical testing of anti-HER3 monoclonal antibodies (mAbs) such as patritumab could not show remarkable effect compared with existing drugs, we generated novel mAbs against anti-HER3. Novel ra...
Source: Oncotarget - February 1, 2020 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Characterization of T ‐DM1‐resistant breast cancer cells
AbstractThe development of targeted therapies has drastically improved the outcome of patients with different types of cancer. T ‐DM1 (trastuzumab‐emtansine) is an antibody‐drug conjugate used for the treatment of HER2‐positive breast cancer combining the FDA approved mAb (monoclonal antibody) trastuzumab and the microtubule cytotoxic agent DM1 (emtansine). Despite clinical successes achieved by targeted therapies, a large number of patients develop resistance during treatment. To explore mechanisms of resistance to T‐DM1, the MDA‐MB‐361 HER2‐positive breast cancer cell line was exposed in vitro to T‐DM1 ...
Source: Pharmacology Research and Perspectives - June 23, 2020 Category: Drugs & Pharmacology Authors: Juliette Sauveur, Louise Conilh, Sabine Beaumel, Kamel Chettab, Lars ‐Petter Jordheim, Eva‐Laure Matera, Charles Dumontet Tags: ORIGINAL ARTICLE Source Type: research

ASAP Systemic Delivery of Aptamer-Conjugated XBP1 siRNA Nanoparticles for Efficient Suppression of HER2+ Breast Cancer
ACS Applied Materials& InterfacesDOI: 10.1021/acsami.0c07353
Source: ACS Applied Materials and Interfaces - July 10, 2020 Category: Materials Science Authors: Long Zhang †§‡, Chaofeng Mu?‡, Tinghong Zhang†§, Yingying Wang†§, Yili Wang†§, Luhui Fan?, Cong Liu?, Hao Chen†§, Jianliang Shen*†§, Kun Wei*†§, and Huaqiong Li*†§ Source Type: research